Ontario makes it stop. For life.

The Ontario Region takes in a large collection of towns and cities that are home to a diverse and ever-growing population. Ontario is the home of a strong community of volunteers, donors and sponsors, as well as an innovative team of researchers and healthcare professionals. These people are the heart and soul of our organization, and there are so many exciting ways to get involved! Every volunteer, donor, researcher and sponsor helps us to improve the lives of those affected by Crohn’s disease and ulcerative colitis, and brings us closer to finding cures.

We welcome newcomers – contact us today and, together, we’ll make it stop. For life.

Ontario Regional Director
Josephine Cavarra
416-920-5035 ext. 244

Development Coordinator, Eastern Ontario
Meera Manghani
647-684-6894

Development Coordinator, Central Ontario
Cindy Weiss
416-920-5035 ext. 239

Development Coordinator, Southwestern Ontario
Lisa Milligan
519-496-6703

Community Engagement Coordinator & Trainer​
Josephine Cavarra
416-920-5035 ext. 244

Development Coordinator, Northern Ontario
Nicole Sage
705-890-9782

Speaker giving a presentation

Diet Interventions for IBD: The Anti-inflammatory Diet and Gut Microbiome

Join us to learn about the relationship between diet and inflammatory bowel disease (IBD), including dietary interventions that target the intestinal microbiome (community of microorganisms in the gut ...

 • 
Zoom (Online)
 • 
Young Adult Series logo

Young Adult Series (Virtual Event)

The Young Adult Series is a unique opportunity for youth 17 to 30 years of age that are living with Inflammatory Bowel Disease (IBD) to connect with others that know what it is like to live with Crohn ...

 • 
Zoom (Online)
 • 
Remember to bookmark this page.

Toronto Office

2110-439 University Avenue
Toronto, ON M5G 1Y8

416-920-5035 or 1-800-387-1479

Search by Postal Code

News

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

 1 2 3 4 5 6 7 8 9 10